3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine , >95% , 50-49-7

CAS NO.：50-49-7

Empirical Formula: C19H24N2

Molecular Weight: 280.41

MDL number: MFCD00242921

EINECS: 200-042-1

PRODUCT Properties

• Melting point: 174°C
• Boiling point: bp0.1 160°
• Density: 0.9935 (rough estimate)
• refractive index: 1.5640 (estimate)
• pka: pKa 9.66(H2O,t = 25,I=0.025) (Uncertain)
• form: Liquid
• color: Colorless to light yellow
• Water Solubility: 18.23mg/L(24 ºC)
• Solvent: Ethanol under nitrogen
• Concentration: 1 mCi/ml
• Specific Activity: 60-90 Ci/mmol
• BCS Class: 1
• EPA Substance Registry System: Imipramine (50-49-7)

Description and Uses

Imipramine is used in depression of various etiology accompanied by motor clumsiness and enuresis in children and Parkinson’s disease.

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Danger
• Hazard statements: H302-H336-H370-H400
• Precautionary statements: P261-P280-P305+P351+P338-P304+P340-P271-P312-P405-P403+P233-P260-P264-P270-P307+P311-P321-P405-P501-P391
• Hazardous Substances Data: 50-49-7(Hazardous Substances Data)
• Toxicity: A tertiary amine tricyclic antidepressant that is thought to exert its therapeutic effect by inhibiting the reuptake of serotonin and norepinephrine centrally. A major metabolite is N-desmethylimipramine (desipramine), also used as an antidepressant drug. Desipramine differs from imipramine in being a better blocker of norepinephrine, rather than serotonin, uptake. Side effects, including sedation and drowsiness, dry mouth, urinary retention, constipation, and orthostatic hypotension, are probably due to the anticholinergic, anti-α-adrenergic, and antihistaminergic receptor-blocking properties. Imipramine should not be used in conjunction with a monoamine oxidase inhibitor or other treatment that increases catecholamine concentrations (e.g., drugs containing sympathomimetic amines). Imipramine should be avoided in patients with cardiovascular disease or seizure disorder, or in those who may abuse alcohol, as imipramine lowers seizure threshold, can produce cardiovascular toxicity and may potentiate the effects of alcohol. Imipramine intoxication can include CNS abnormalities (e.g., drowsiness, stupor, coma, and extrapyramidal symptoms), cardiac arrhythmia, and respiratory depression. Children appear to be particularly vulnerable to the cardiotoxic and seizure-inducing effects of high doses of imipramine. The oral LD50 in female rats is 305 mg/kg.